Whitehawk Therapeutics, Inc. financial data

Symbol
WHWK on Nasdaq
Location
Morristown, NJ
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 12 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1598% % 258%
Quick Ratio 0% % -100%
Debt-to-equity 6.6% % -75%
Return On Equity -12% % 86%
Return On Assets -11% % 84%
Operating Margin -1601% % -517%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 47,196,564 shares 0.88%
Common Stock, Shares, Outstanding 47,145,719 shares 91%
Entity Public Float $64,900,000 USD 166%
Common Stock, Value, Issued $4,000 USD 100%
Weighted Average Number of Shares Outstanding, Basic 61,886,765 shares 129%
Weighted Average Number of Shares Outstanding, Diluted 61,886,765 shares 129%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $7,145,000 USD -73%
Research and Development Expense $90,963,000 USD 78%
Costs and Expenses $121,545,000 USD 30%
Operating Income (Loss) $114,400,000 USD -70%
Income Tax Expense (Benefit) $0 USD
Net Income (Loss) Attributable to Parent $20,596,000 USD 68%
Earnings Per Share, Basic -0.33 USD/shares 86%
Earnings Per Share, Diluted -0.33 USD/shares 86%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $37,568,000 USD 31%
Cash, Cash Equivalents, and Short-term Investments $145,700,000 USD 209%
Accounts Receivable, after Allowance for Credit Loss, Current $0 USD -100%
Inventory, Net $0 USD -100%
Assets, Current $149,013,000 USD 143%
Property, Plant and Equipment, Net $3,000 USD -100%
Operating Lease, Right-of-Use Asset $0 USD -100%
Other Assets, Noncurrent $1,814,000 USD 30%
Assets $150,830,000 USD 114%
Accounts Payable, Current $917,000 USD -58%
Accrued Liabilities, Current $8,216 USD
Liabilities, Current $14,519,000 USD -15%
Operating Lease, Liability, Noncurrent $0 USD -100%
Other Liabilities, Noncurrent $0 USD -100%
Liabilities $14,519,000 USD -19%
Accumulated Other Comprehensive Income (Loss), Net of Tax $120,000 USD 650%
Retained Earnings (Accumulated Deficit) $353,250,000 USD -6.2%
Stockholders' Equity Attributable to Parent $136,311,000 USD 160%
Liabilities and Equity $150,830,000 USD 114%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $11,864,000 USD 40%
Net Cash Provided by (Used in) Financing Activities $10,000 USD -225%
Net Cash Provided by (Used in) Investing Activities $115,498,000 USD 994%
Common Stock, Shares Authorized 300,000,000 shares 0%
Common Stock, Shares, Issued 47,145,719 shares 91%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $198,835,000 USD
Interest Paid, Excluding Capitalized Interest, Operating Activities $0 USD -100%
Deferred Tax Assets, Valuation Allowance $44,579,000 USD -63%
Operating Lease, Liability $0 USD -100%
Depreciation $100,000 USD -50%
Payments to Acquire Property, Plant, and Equipment $551,000 USD -25%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $20,492,000 USD 68%
Lessee, Operating Lease, Liability, to be Paid $940,000 USD -35%
Property, Plant and Equipment, Gross $377,000 USD -95%
Operating Lease, Liability, Current $0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Two $231,000 USD -28%
Lessee, Operating Lease, Liability, to be Paid, Year One $320,000 USD -38%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $107,000 USD -42%
Lessee, Operating Lease, Liability, to be Paid, Year Three $280,000 USD 21%
Deferred Tax Assets, Operating Loss Carryforwards $26,496,000 USD -46%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $207,000 USD -96%
Lessee, Operating Lease, Liability, to be Paid, Year Four $109,000 USD -61%
Operating Lease, Payments $99,000 USD -21%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $50,000 USD 32%
Deferred Tax Assets, Net of Valuation Allowance $115,000 USD -71%
Interest Expense $231,000 USD 0.44%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%